open access

Vol 5, No 3 (2016)
Pharmaceutical news
Get Citation

Empagliflozin. Results of the EMPA-REG OUTCOME trial. A breakthrough in treatment of type 2 diabetes?

Krzysztof Strojek, Dominika Rokicka, Aleksandra Szymborska-Kajanek, Marta Wróbel
DOI: 10.5603/DK.2016.0018
·
Clinical Diabetology 2016;5(3):107-110.

open access

Vol 5, No 3 (2016)
Pharmaceutical news

Abstract

Cardiovascular (CV) complications are the main health challenge among type 2 diabetic patients. They may cause premature death, disability and reduce the quality of life. Administering a multifactorial intervention aimed at controlling glycaemia, lipaemia and arterial blood pressure allows to reduce the risk of their occurrence. FDA ruled that all newly introduced hypoglycaemic agents must undergo tests for CV safety. The EMPAREG OUTCOME trial was conducted on a group of type 2 diabetic patients at high CV risk. It showed that including empagliflozin in the standard therapy reduces the risk of primary outcome (death from CV causes, non-fatal myocardial infarction or non-fatal stroke) by 14% and all-cause mortality by 32%. The causes of this effect of empagliflozin — an inhibitor of SGLT2, which is an enzyme present only in renal proximal tubules — are unclear. Reduction in insulin resistance and in oxidative stress, changes in lipid levels, reduction in uric acid levels, in albuminuria, in blood pressure and reduction in sympathetic activity are all named as potential mechanisms underlying the  rotective effect of empagliflozin.

Results of the EMPA-REG OUTCOME trial are a breakthrough in the treatment of diabetes, and if other SGLT2 inhibitors are found to have similar effects, a fundamental change in therapy recommendations for this patient population may be made.

Abstract

Cardiovascular (CV) complications are the main health challenge among type 2 diabetic patients. They may cause premature death, disability and reduce the quality of life. Administering a multifactorial intervention aimed at controlling glycaemia, lipaemia and arterial blood pressure allows to reduce the risk of their occurrence. FDA ruled that all newly introduced hypoglycaemic agents must undergo tests for CV safety. The EMPAREG OUTCOME trial was conducted on a group of type 2 diabetic patients at high CV risk. It showed that including empagliflozin in the standard therapy reduces the risk of primary outcome (death from CV causes, non-fatal myocardial infarction or non-fatal stroke) by 14% and all-cause mortality by 32%. The causes of this effect of empagliflozin — an inhibitor of SGLT2, which is an enzyme present only in renal proximal tubules — are unclear. Reduction in insulin resistance and in oxidative stress, changes in lipid levels, reduction in uric acid levels, in albuminuria, in blood pressure and reduction in sympathetic activity are all named as potential mechanisms underlying the  rotective effect of empagliflozin.

Results of the EMPA-REG OUTCOME trial are a breakthrough in the treatment of diabetes, and if other SGLT2 inhibitors are found to have similar effects, a fundamental change in therapy recommendations for this patient population may be made.

Get Citation

Keywords

diabetes type 2, cardiovascular complications, SGLT2 inhibitors, EMPA-REG OUTCOME

About this article
Title

Empagliflozin. Results of the EMPA-REG OUTCOME trial. A breakthrough in treatment of type 2 diabetes?

Journal

Clinical Diabetology

Issue

Vol 5, No 3 (2016)

Pages

107-110

DOI

10.5603/DK.2016.0018

Bibliographic record

Clinical Diabetology 2016;5(3):107-110.

Keywords

diabetes type 2
cardiovascular complications
SGLT2 inhibitors
EMPA-REG OUTCOME

Authors

Krzysztof Strojek
Dominika Rokicka
Aleksandra Szymborska-Kajanek
Marta Wróbel

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Diabetologia Kliniczna dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl